| Identification | More | [Name]
Sodium risedronate | [CAS]
115436-72-1 | [Synonyms]
[1-hydroxy-2-(3-pyridinyl)ethylidene]-bis[phosphonic acid] monosodium salt
RISEDREMATE SODIUM
RISEDRONATE NA
RISEDRONATE SODIUM
RISEDRONIC ACID, SODIUM SALT
SODIUM RISEDRONATE
(1-hydroxy-2-(3-pyridinyl)ethylidene)bis-phosphonicacimonosodiumsalt
monosodium(1-hydroxy-2-(3-pyridinyl)ethylidene)bisphosphonate
Risedronat sodium
RisedronateSodium&Int.
[1-Hydroxy-2-(3-pyridinyl)ethylidene]-bis[phosphonicacid]monosodiumsalthemi-pentahydrate
Actonel
NE 58095
Risedronic Acid Monosodium Salt
risedronate，RID
1-Hydroxy-2-(3-pyridinyl)ethylidenebisphosphonatemonosodiumhemipentahydrate
RISENDRONATE SODIUM | [EINECS(EC#)]
1806241-263-5 | [Molecular Formula]
C7H10NNaO7P2 | [MDL Number]
MFCD01706268 | [Molecular Weight]
305.09 | [MOL File]
115436-72-1.mol |
| Chemical Properties | Back Directory | [Appearance]
Fine White to Off-White Crystalline Powder | [Melting point ]
252-262°C | [storage temp. ]
room temp | [solubility ]
H2O: soluble5mg/mL, clear (warmed) | [form ]
powder | [color ]
white to beige | [Water Solubility ]
Soluble to 10 mM in water | [Usage]
A pyridinyl biphosphonate bone resorption inhibitor. | [BCS Class]
3 | [Stability:]
Hygroscopic | [CAS DataBase Reference]
115436-72-1(CAS DataBase Reference) |
| Hazard Information | Back Directory | [Hazard]
Human systemic effects.
| [Chemical Properties]
Fine White to Off-White Crystalline Powder | [Originator]
Procter Gamble (US) | [Uses]
antibacterial | [Uses]
Osteoporosis | [Uses]
Risedronic Acid is a pyridinyl biphosphonate bone resorption inhibitor. | [Definition]
ChEBI: Risedronate sodium is a 1,1-bis(phosphonic acid). | [Brand name]
Actonel (Procter & Gamble). | [Biological Activity]
Orally active biphosphonate that inhibits farnesyl diphosphate (FPP) synthase. Exhibits antiproliferative and proapoptotic activity in numerous tumor cell lines and inhibits osteoclast-mediated bone reabsorption in vivo . | [Biochem/physiol Actions]
Risedronate sodium is a bisphosphonate bone resorption inhibitor. It has an affinity for hydroxyapatite crystals in bone and acts as an antiresorptive agent and is an inhibitor of farnesyl diphosphate (FPP) synthase, which results in downstream inhibition of osteoclast activity and reduced bone resorption and turnover. Risedronate sodium has been used to treat postmenopausal osteoporosis and Paget′s disease. | [Clinical Use]
Bisphosphonate:
Treatment and prevention of osteoporosis (including
corticosteroid induced)
Paget’s disease | [Drug interactions]
Potentially hazardous interactions with other drugs
Calcium-containing substances: avoid for 2 hours
before and after administration. | [Metabolism]
The mean bioavailability of risedronate is 0.63% in
the fasting state, and there is no evidence of systemic
metabolism of risedronate sodium.
About half of the absorbed portion is excreted in the
urine within 24 hours; the remainder is sequestered
to bone for a prolonged period. Unabsorbed drug is
eliminated unchanged in the faeces. | [storage]
Store at -20°C |
| Questions And Answer | Back Directory | [Description]
Risedronate sodium is a nitrogen-containing bisphosphonate that inhibits osteoclast-mediated bone resorption and modulates bone metabolism.
Risedronate sodium is used for the treatment of postmenopausal osteoporosis to reduce the risk of vertebral fractures, treatment of established postmenopausal osteoporosis to reduce the risk of hip fractures, treatment of osteoporosis in men at high risk of fractures, and treatment of Paget’s disease. It is marketed as Actonel (tablet) and Atelvia (delayed-release tablet).
| [References]
[1] https://www.medicines.org.uk
[2] http://www.rxlist.com
[3] http://www.healthline.com
|
|
|